PL2173324T3 - Zastosowanie żelu z polisacharydu(ów) naturalnego(ych) do wytwarzania kompozycji do wstrzykiwania w celu leczenia zwyrodnień stawów - Google Patents

Zastosowanie żelu z polisacharydu(ów) naturalnego(ych) do wytwarzania kompozycji do wstrzykiwania w celu leczenia zwyrodnień stawów

Info

Publication number
PL2173324T3
PL2173324T3 PL08827889T PL08827889T PL2173324T3 PL 2173324 T3 PL2173324 T3 PL 2173324T3 PL 08827889 T PL08827889 T PL 08827889T PL 08827889 T PL08827889 T PL 08827889T PL 2173324 T3 PL2173324 T3 PL 2173324T3
Authority
PL
Poland
Prior art keywords
hyaluronic acid
injectable gel
treating joint
joint degeneration
acid injectable
Prior art date
Application number
PL08827889T
Other languages
English (en)
Inventor
Samuel Gavard Molliard
Olivier Benoit
Original Assignee
Aptissen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39167393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2173324(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptissen Sa filed Critical Aptissen Sa
Publication of PL2173324T3 publication Critical patent/PL2173324T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
PL08827889T 2007-07-02 2008-07-02 Zastosowanie żelu z polisacharydu(ów) naturalnego(ych) do wytwarzania kompozycji do wstrzykiwania w celu leczenia zwyrodnień stawów PL2173324T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0704772A FR2918276B1 (fr) 2007-07-02 2007-07-02 "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
PCT/FR2008/000948 WO2009024670A2 (fr) 2007-07-02 2008-07-02 Gel injectable d ' acide hyaluronique pour le traitement des degenerescences articulaires
EP08827889.0A EP2173324B1 (fr) 2007-07-02 2008-07-02 Gel injectable d'acide hyaluronique pour le traitement des degenerescences articulaires

Publications (1)

Publication Number Publication Date
PL2173324T3 true PL2173324T3 (pl) 2019-09-30

Family

ID=39167393

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19156054T PL3498262T3 (pl) 2007-07-02 2008-07-02 Kwas hialuronowy - żel do wstrzykiwania
PL08827889T PL2173324T3 (pl) 2007-07-02 2008-07-02 Zastosowanie żelu z polisacharydu(ów) naturalnego(ych) do wytwarzania kompozycji do wstrzykiwania w celu leczenia zwyrodnień stawów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19156054T PL3498262T3 (pl) 2007-07-02 2008-07-02 Kwas hialuronowy - żel do wstrzykiwania

Country Status (14)

Country Link
US (1) US9138405B2 (pl)
EP (2) EP3498262B1 (pl)
JP (1) JP5517133B2 (pl)
KR (1) KR20100028582A (pl)
CN (2) CN104825482A (pl)
BR (1) BRPI0813011B8 (pl)
CA (1) CA2691600C (pl)
ES (2) ES2735376T3 (pl)
FR (1) FR2918276B1 (pl)
HU (1) HUE056793T2 (pl)
PL (2) PL3498262T3 (pl)
PT (2) PT3498262T (pl)
TR (1) TR201909779T4 (pl)
WO (1) WO2009024670A2 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945949B1 (fr) * 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
FR2954165B1 (fr) * 2009-12-18 2012-01-13 Jean-Noel Thorel Compositions injectables a usage intra-articulaire associant un agent de viscosupplementation et un milieu de croissance des fibroblastes
JP5457238B2 (ja) * 2010-03-17 2014-04-02 電気化学工業株式会社 ヒアルロン酸及び／又はその塩の含有液の加熱滅菌方法
IT1402382B1 (it) 2010-09-09 2013-09-04 Ibsa Inst Biochimique Sa Complessi cooperativi ibridi di acido ialuronico
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
WO2012143876A1 (en) * 2011-04-19 2012-10-26 Anteis S.A. A sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
GB201118586D0 (en) * 2011-10-27 2011-12-07 Turzi Antoine New A-PRP medical device, manufacturing machine and process
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
WO2013076162A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Formulations useful in the treatment of osteoarticular diseases
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
JP2016506909A (ja) * 2013-01-11 2016-03-07 カービラン セラピューティクス， インコーポレイテッド ヒアルロン酸を含む安定化組成物
ES2837626T3 (es) * 2013-07-10 2021-07-01 Matrix Biology Inst Composiciones de hialuronano con alta elasticidad y usos de las mismas
KR101582380B1 (ko) * 2013-09-11 2016-01-05 주식회사 제네웰 손상 조직에 대한 세포 전달 및 조직 재생용 생체재료와 제조방법
CA2931726C (en) 2013-11-25 2022-03-15 Deuteria Biomaterials, Llc Deuterium-enriched hyaluronan
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
FR3032617B1 (fr) * 2015-02-16 2018-03-16 Kylane Laboratoires Sa Procede de preparation d un hydrogel injectable; hydrogel obtenu; utilisation de l hydrogel obtenu
PT3352766T (pt) 2015-09-24 2022-03-22 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
CN105879124B (zh) * 2016-04-26 2019-03-19 华熙福瑞达生物医药有限公司 一种注射用左旋聚乳酸填充剂及其制备方法
KR101916193B1 (ko) 2016-08-25 2018-11-07 주식회사 파마리서치프로덕트 핵산 및 키토산을 포함하는 관절강 주사용 조성물
US10576099B2 (en) 2016-10-21 2020-03-03 Covidien Lp Injectable scaffold for treatment of intracranial aneurysms and related technology
FR3063649B1 (fr) * 2017-03-07 2021-05-21 Laboratoire De Rhumatologie Appliquee Nouvelle solution visco-elastique et son utilisation en rhumatologie
NZ761298A (en) * 2017-08-22 2024-03-22 Moebius Medical Ltd Liposomal formulation for joint lubrication
IT201800007683A1 (it) 2018-07-31 2020-01-31 Altergon Sa Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati
KR102566287B1 (ko) * 2018-11-30 2023-08-11 주식회사 엘지화학 히알루론산을 포함하는 활액보충재용 조성물
WO2020154305A1 (en) 2019-01-21 2020-07-30 Eclipse Medcorp, Llc Methods, systems and apparatus for separating components of a biological sample
KR20220091580A (ko) 2019-10-31 2022-06-30 이클립스 메드코프 엘엘씨 샘플의 구성요소들을 분리하기 위한 시스템, 방법 및 장치
EP3854377A1 (fr) * 2020-01-22 2021-07-28 Laboratoires Genevrier Sas Composition comprenant de l'acide hyaluronique et un polyol ou de carboxyméthylcellulose

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5079236A (en) 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
IL86933A (en) * 1987-07-01 1993-07-08 Genentech Inc Method and therapeutic compositions for the prevention of fibrin deposition for adhesions
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
JP2788340B2 (ja) * 1989-12-21 1998-08-20 株式会社ニッショー 炎症治療剤
AU652022B2 (en) * 1991-02-12 1994-08-11 C.R. Bard Inc. Injectable medical device
US7968110B2 (en) * 1992-02-11 2011-06-28 Merz Aesthetics, Inc. Tissue augmentation material and method
IT1291291B1 (it) * 1997-04-30 1999-01-07 Chemedica Sa Uso di acido ialuronico e relativi sali per la preparazione di una soluzione acquosa utile come liquido di lavaggio intra-articolare
EP1465596A1 (en) * 2002-01-18 2004-10-13 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
AU2003206922A1 (en) 2003-02-19 2004-09-09 Aventis Pharmaceuticals Holdings Inc. Composition and method for intradermal soft tissue augmentation
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
FR2865737B1 (fr) * 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible
US20050215516A1 (en) 2004-03-29 2005-09-29 Claudio Bucolo New free-radical scavenger containing viscoelastic composition, methods of use and package
EP1781305A2 (en) * 2004-08-13 2007-05-09 Angiotech International Ag Compositions and methods using hyaluronic acid and hyaluronidase inhibitors
WO2006067608A1 (en) * 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
FR2895907B1 (fr) * 2006-01-06 2012-06-01 Anteis Sa Gel viscoelastique a usage dermatologique
FR2909560B1 (fr) 2006-12-06 2012-12-28 Fabre Pierre Dermo Cosmetique Gel d'acide hyaluronique pour injection intradermique

Also Published As

Publication number Publication date
ES2898939T3 (es) 2022-03-09
EP3498262A1 (fr) 2019-06-19
PT2173324T (pt) 2019-07-09
FR2918276B1 (fr) 2010-01-22
PL3498262T3 (pl) 2022-02-07
KR20100028582A (ko) 2010-03-12
EP2173324B1 (fr) 2019-04-10
CA2691600A1 (fr) 2009-02-26
BRPI0813011A2 (pt) 2014-12-23
EP3498262B1 (fr) 2021-09-01
WO2009024670A2 (fr) 2009-02-26
ES2735376T3 (es) 2019-12-18
CN101686936A (zh) 2010-03-31
BRPI0813011B8 (pt) 2021-05-25
CN104825482A (zh) 2015-08-12
US9138405B2 (en) 2015-09-22
BRPI0813011B1 (pt) 2019-10-08
FR2918276A1 (fr) 2009-01-09
TR201909779T4 (tr) 2019-07-22
US20100184720A1 (en) 2010-07-22
HUE056793T2 (hu) 2022-03-28
JP2010531863A (ja) 2010-09-30
JP5517133B2 (ja) 2014-06-11
PT3498262T (pt) 2021-11-11
EP2173324A2 (fr) 2010-04-14
CA2691600C (fr) 2017-01-10
WO2009024670A3 (fr) 2009-04-23

Similar Documents

Publication Publication Date Title
PL2173324T3 (pl) Zastosowanie żelu z polisacharydu(ów) naturalnego(ych) do wytwarzania kompozycji do wstrzykiwania w celu leczenia zwyrodnień stawów
HK1197040A1 (en) Sulphated hyaluronic acid for treating degenerative osteoarthritis
EP2285310A4 (en) JOINT PROSTHESIS
EP2360188A4 (en) HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
EP2344078A4 (en) SYSTEMS AND METHOD FOR GEAR KIT
IL220434A (en) Knee repair implant system
IL214848A0 (en) Systems and methods for facet joint treatment
HUE047058T2 (hu) Liofilizációs módszer
HK1142917A1 (en) Tunably crosslinked hyaluronic acid compositions
EP2259753A4 (en) JOINT IMPLANT WITH ADJUSTED EDGE
PL2445510T3 (pl) Kompozycja do leczenia zwyrodnieniowych chorób stawów
EP2339985A4 (en) METHOD FOR STORING ORTHOPEDIC ROLLING DEVICES ON A TRAIN-BASED BASE
EP2333393A4 (en) JOINT UNIT
ZA201007740B (en) Joint prosthesis
WO2010123759A9 (en) Compositions and methods for treating burns
EP2114457A4 (en) COMPOSITION TO PROMOTE BONE REGENERATION AND RECONSTRUCTION
ZA201102967B (en) Facet joint prosthesis
PL2339992T3 (pl) Implant stawowy
EP2440159A4 (en) JOINT IMPLANT
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
GB0805122D0 (en) Replacement bone joints
ZA201100969B (en) Pharmaceutical composition having relatively low ionic strength
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
GB0715397D0 (en) Treatment for joint disease
GB0811637D0 (en) Hyaluronic acid crtogel